Share on LinkedInShare on LinkedIn

ARTICLE · 18 JUNE 2026

Current Counterfeit Challenges In The UK Pharmaceutical Sector

Lewis Silkin
Lewis Silkin
Contributor
Lewis Silkin

Lewis Silkin

Joint managing partners: Jo Farmer, Richard Miskella International offices: Dublin, Hong Kong...

View firm profile
Explore more from Lewis Silkin

The UK pharmaceutical sector faces significant challenges from counterfeit medicines that threaten patient safety and undermine legitimate supply chains. This analysis examines the current landscape of pharmaceutical counterfeiting...

United KingdomConsumer Protection

The topic of counterfeit medicines was discussed at the recent PTMG (Pharmaceutical Trade Marks Group) Spring conference in Munich. This article explores the situation in the UK and ways in which the issue is being addressed.

Earlier this year, the Medicines and Healthcare products Regulatory Agency ("MHRA"), the UK regulator of medicines, medical devices, and blood components for transfusion, responsible for making sure these products meet set standards for safety, quality and efficacy, published a press release stating that it had seized illegal medicines worth almost £45 million in 2025.

The MHRA's action prevented nearly 20 million doses of potentially dangerous medicines from reaching the public. Counterfeit medicines contain harmful substances or incorrect dosages which can harm health. The counterfeit medicines will usually include logos, brand names, labels, packaging, colour combinations, shapes or design elements identical or deceptively similar to those used by

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from